HRT
HRT After Breast Cancer
When HRT can be considered, and what non-hormonal options are best supported by evidence.
Systemic HRT after breast cancer needs multidisciplinary input. Vaginal oestrogen at licensed doses is often considered acceptable after specialist review.
Menopausal symptoms after breast cancer are common, severe and often under-treated. Chemotherapy, tamoxifen, aromatase inhibitors and ovarian suppression all drive abrupt, deep menopause — sometimes in women in their 30s. The conversation about hormone replacement is nuanced, deeply personal, and best held between an experienced menopause clinician and your oncology team together. What has changed in recent years is the recognition that ‘no HRT ever’ is not a compassionate default: many non-hormonal and local-hormonal options are safe, effective and quality-of-life-transforming, and even systemic HRT is sometimes appropriate after careful shared decision-making.
What we usually consider acceptable
- Low-dose vaginal (local) oestrogen for genitourinary syndrome — after discussion with oncology, and often preferred for women on tamoxifen. For women on aromatase inhibitors, prasterone or non-hormonal options are usually tried first.
- Non-hormonal medications for hot flushes: paroxetine, venlafaxine, citalopram, gabapentin, clonidine, oxybutynin, and fezolinetant (Veoza) — the new neurokinin-3 antagonist that is a genuine advance for this group.
- Cognitive behavioural therapy (CBT) for hot flushes — good evidence from the MENOS-1 trial, particularly in women after breast cancer.
- Vaginal moisturisers and lubricants used consistently — a small change that transforms comfort.
- Bone protection: DEXA scan, calcium, vitamin D and, where indicated, bisphosphonates or denosumab — especially on aromatase inhibitors, which accelerate bone loss.
When systemic HRT can be considered
- Very rarely as a first-line option, but for a subset of women with severe, disabling symptoms unresponsive to non-hormonal treatment, systemic HRT may be discussed after full oncology input and a documented informed-consent conversation.
- The decision depends on tumour type (hormone receptor status, HER2), stage, time since diagnosis, current endocrine therapy, other risk factors, and the woman’s own values.
- Oestrogen-only regimens after hysterectomy have a different risk profile from combined regimens.
- Body-identical micronised progesterone appears to carry a more favourable profile than older synthetic progestogens.
Where nuance really matters
- Time since treatment: many oncologists are more open to discussion after 5 years disease-free.
- Current endocrine therapy: HRT is generally not combined with tamoxifen or aromatase inhibitors.
- Symptom severity: quality-of-life-limiting symptoms — inability to work, severe depression, catastrophic sleep — change the calculus.
- Fracture risk on aromatase inhibitors can be substantial; systemic bone protection is essential even without HRT.
Bones and heart after breast cancer
- Aromatase inhibitors reduce oestrogen to near-undetectable levels, accelerating bone loss by 2–3% per year — DEXA at baseline and every 2 years.
- Chemotherapy raises cardiovascular risk; annual blood pressure, lipids and HbA1c matter more than ever.
- Strength training, Mediterranean-style eating and daily walking are not optional — they are treatment.
Living well without systemic HRT
- Hot flushes: CBT, venlafaxine, or fezolinetant in the right patient.
- Sleep: CBT-I, low-dose amitriptyline, treatment of restless legs.
- Mood: exercise, therapy, SSRIs where clinically indicated.
- Sex: vaginal oestrogen (after discussion), prasterone, generous moisturisers and lubricants, pelvic floor physio, psychosexual therapy.
- Bones: weight-bearing exercise, calcium and vitamin D, bisphosphonates or denosumab as indicated.
How we approach it in clinic
- Full discussion with your oncology team is the starting point — we write to them, and we share the decision.
- We map every symptom against non-hormonal and local-hormonal options first.
- Where systemic HRT is on the table, we document a full risk-benefit conversation, agree a review interval, and coordinate with your oncologist.
- You retain the right to change your mind at any point.
Key takeaway
You have more options after breast cancer than the initial conversation often suggests. Vaginal oestrogen, fezolinetant, CBT, SSRIs and lifestyle levers together transform quality of life for most women — and systemic HRT remains an option for a carefully selected minority, always shared with your oncology team.
How Dr Awal approaches this in clinic
Every consultation starts with your full story — symptoms, cycle, medical history, family history and what you've already tried. From there we look at whether hormonal treatment, non-hormonal options, lifestyle changes or a combination will give you the best result, and we tailor the plan to your age, risk factors and preferences.
- A detailed 60 minute first appointment — no rushed 10-minute slots.
- Evidence-based recommendations aligned with NICE NG23 and BMS guidance.
- Body-identical HRT considered first-line where appropriate.
- Shared-care letters sent to your NHS GP so treatment can continue affordably.
- Follow-up at 3 months to fine-tune your regimen and address side effects.
- Ongoing annual reviews so your plan evolves with you.
Common questions we hear about this
Do I need to be at a certain age to be seen?
No. We see women in early perimenopause (often late 30s and 40s), through post-menopause and beyond. Age alone doesn't decide whether treatment is right — symptoms, health history and goals do.
Will my GP continue the prescription?
In most cases yes. After your consultation we send a detailed shared-care letter with the diagnosis, treatment plan and rationale so your NHS GP can prescribe on the NHS. Not every practice accepts shared care — we'll discuss this in your appointment.
What if I've tried HRT before and it didn't suit me?
Very common — often the type, dose or route wasn't right rather than HRT itself. We review what you've tried, why it didn't work, and adjust accordingly. Many women who thought HRT wasn't for them do well on a different preparation.
How long will I need to stay on treatment?
There is no set upper time limit for HRT. Current BMS and NICE guidance supports continuing HRT for as long as the benefits outweigh the risks for you personally. We review this together every year so you stay in control of the decision.
Where do you see patients?
All consultations at Pause and Co Healthcare are conducted securely via video, allowing us to support patients anywhere in the UK. Prescriptions and shared care arrangements are managed in the same way, regardless of your location.
About the author
Dr Nadira Awal is a British Menopause Society Advanced Menopause Specialist with 15+ years' NHS and private experience. She holds the BMS Advanced Certificate in Menopause Care, sits on the BMS Programme Planning Group, and advises the UK Government Menopause Strategy Group. Read her full profile.
Sources & further reading
General information only — not a substitute for personalised medical advice. Always speak to your GP or a menopause specialist about your own situation.
Talk it through
Book a private consultation with Dr Awal
Get evidence-based, personalised advice on hrt after breast cancer and any related concerns.
Related in HRT
Continue reading
A Comprehensive Guide to HRT
Types of HRT, oestrogen vs progesterone, benefits, side effects — and how to manage them.
Read guide
NHS vs Private HRT in the UK
How NHS and private HRT compare — costs, wait times, choice of preparations and how to transfer prescriptions.
Read guide
HRT Shortages in the UK
Why HRT supply issues happen, current UK availability and safe swaps if your prescription is unavailable.
Read guide